柳藥股份(603368.SH):萬通製藥被確定為廣西中藥配方顆粒研究試點企業
格隆匯 7 月 1日丨柳藥股份(603368.SH)公佈,近日,公司控股子公司廣西萬通製藥有限公司(“萬通製藥”)收到廣西壯族自治區工業和信息化廳下發的《關於公佈2020年我區中藥配方顆粒研究試點企業名單(第一批)的通知》(紡藥20200010),確定萬通製藥列為廣西壯族自治區中藥配方顆粒研究試點企業。
萬通製藥自設立以來,專注於中成藥的研發、生產和銷售,系廣西著名中成藥生產企業、國家高新技術企業和國家民委認定的少數民族特需商品定點生產企業。萬通製藥於2018年7月取得新版GMP認證,能夠生產片劑、顆粒劑、丸劑、散劑、茶劑、硬膠囊劑等6個劑型超百個品種,同時具有中藥飲片炮製、提取、濃縮、乾燥、制粒等完整生產能力,具備成熟的顆粒劑生產工藝和管理經驗。
中藥配方顆粒研發應用是中藥創新和現代化戰略的重要內容。近年來,在國家《中醫藥創新發展規劃綱要(2006-2020年)》、《關於扶持和促進中醫藥事業發展的若干意見》、《中醫藥發展戰略規劃綱要2016-2030年》等政策的指導推動下,中藥配方顆粒行業處於快速成長期,市場前景廣闊。萬通製藥作為中藥配方顆粒研究試點企業,開展中藥配方顆粒產品生產研發,既符合國家中藥現代化、創新化的發展要求,也符合公司整體戰略規劃,有利於發揮萬通製藥的生產研發優勢,優化公司品種結構,提高公司中藥產品附加值,與公司現有中藥飲片生產加工形成良好的業務協同,進一步完善公司中醫藥全產業鏈業務體系,從而持續提升公司盈利能力和綜合競爭力,形成公司新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.